SCHEMBL1711344

SCHEMBL1711344

O=C(c1ccccc1)c1ccccc1C1Cc2ccccc2OC1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.38
SIRT1 Q96EB6 1/20 0.38
AKR1C3 P42330 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HSP90AA1 P07900 1/20 0.38
PKM P14618 1/20 0.38
CCR6 P51684 1/20 0.38
ATM Q13315 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TLR9 Q9NR96 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
KLK5 Q9Y337 1/20 0.37
GAA P10253 2/20 0.36
MAPT P10636 1/20 0.36
PPARG P37231 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
CYP2C8 P10632 1/20 0.34
AKR1C2 P52895 1/20 0.34
AKR1C1 Q04828 1/20 0.34
ESR1 P03372 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28596601 0.77 ALDH1A1 (0.47) SIRT1ALDH1A1MAPTPPARG
SCHEMBL29629334 0.77 ALDH1A1 (0.47) SIRT1ALDH1A1MAPTPPARG
SCHEMBL28596603 0.77 ALDH1A1 (0.47) SIRT1ALDH1A1MAPTPPARG
SCHEMBL754483 0.77 AR (0.46) SIRT1AKR1C3ALDH1A1KLK5GAA
SCHEMBL2848169 0.75 TP53 (0.42) SIRT1ALDH1A1KLK5MAPTSMN1; SMN2
SCHEMBL27893072 0.74 SIRT1 (0.48) SIRT1ALDH1A1KLK5GAAPPARG
SCHEMBL72984 0.74 SIRT1 (0.48) SIRT1ALDH1A1KLK5GAAPPARG
SCHEMBL11527078 0.73 PPARG (0.57) SIRT1ALDH1A1KLK5GAAMAPT
Charcoal, Activated SCHEMBL2025121 0.72 SIRT1 (0.47) SIRT1ALDH1A1KLK5GAAPPARG
SCHEMBL2992253 0.69 KLK5 (0.52) SIRT1ALDH1A1KLK5GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344462-B1 PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE UNIV DUNDEE (GB) 2016-05-18 EP disclosed
US-8563557-B2 Pyrimidine derivatives and their pharmaceutical use UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2013-10-22 US disclosed
US-20110245282-A1 Compounds University Court of the University of Dundee University Court of the University of St. Andrews 2011-10-06 US disclosed
EP-2344462-A1 PYRIMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE The University Court of the University of Dundee (GB) 2011-07-20 EP disclosed
WO-2010038043-A1 PYRIMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245282-A1 Compounds NAT1, AR, ARSA CYP2C9 78/4885SIRT1 1567/4885AKR1C3 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.